Saikosaponin D loaded macrophage membrane-biomimetic nanoparticles target angiogenic signaling for breast cancer therapy

Sun, Kaiju; Yu, Wei; Bai, Jing; Chen, Changbao; Yang, Hongmei; Du, Yangyang; Song, Mingming; Cai, Hongqiao; Yan, Fei; Su, Rui

doi:10.1016/j.apmt.2019.100505

Cited by 53 publications

(47 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells were washed twice with ice-cold PBS and lysed using ice-cold RIPA lysis buffer containing proteases. Western blot analysis of the cell protein lysates was performed as described previously 34 . The following antibodies were purchased respectively from Cell Signaling Technology: anti-FTO (#31687), anti-RARA (#2554), anti-MYC (#9402), anti-METTL3 (#86132), anti-YTHDF2 (#80014), anti-FLT3 (#3462), anti-Bcl-2 (#15071), anti-Stat3 (#9139); from Abcam: anti-ALKBH5 (ab244296); from Santa Cruz: Anti-β-Actin (#sc47778); and from Thermo Fisher: Anti-puromycin (#BP2956).…”

Section: Methodsmentioning

confidence: 99%

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling

Sun

Hou

et al. 2021

Theranostics

Self Cite

View full text Add to dashboard Cite

Purpose: The implementation of targeted therapies for acute myeloid leukemia (AML) has been challenging. Fat mass and obesity associated protein (FTO), an mRNA N 6 -methyladenosine (m 6 A) demethylase, functions as an oncogene that promotes leukemic oncogene-mediated cell transformation and leukemogenesis. Here, we investigated the role of Saikosaponin-d (SsD) in broad anti-proliferation effects in AML and evaluated the m 6 A demethylation activity by targeting FTO of SsD. Methods: It was examined whether and how SsD regulates FTO/m 6 A signaling in AML. The pharmacologic activities and mechanisms of actions of SsD in vitro , in mice, primary patient cells, and tyrosine kinase inhibitors-resistant cells were determined. Results: SsD showed a broadly-suppressed AML cell proliferation and promoted apoptosis and cell-cycle arrest both in vitro and in vivo . Mechanistically, SsD directly targeted FTO, thereby increasing global m 6 A RNA methylation, which in turn decreased the stability of downstream gene transcripts, leading to the suppression of relevant pathways. Importantly, SsD also overcame FTO/m 6 A-mediated leukemia resistance to tyrosine kinase inhibitors. Conclusion: Our findings demonstrated that FTO-dependent m 6 A RNA methylation mediated the anti-leukemic actions of SsD, thereby opening a window to develop SsD as an epitranscriptome-base drug for leukemia therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling

Sun

Hou

et al. 2021

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Su et al [ 66 ] have developed Saikosaponin D loaded macrophage membrane-biomimetic nanoparticles (SCMNPs) for breast cancer therapy. This nano-drug system consists of a poly (latic-co-glycolic acid) nanoparticles and macrophage membrane hybridized with T7 peptide.…”

Section: Macrophage Membranesmentioning

confidence: 99%

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Gong

Wang

Zhang

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite the advances in surface bioconjugation of synthetic nanoparticles for targeted drug delivery, simple biological functionalization is still insufficient to replicate complex intercellular interactions naturally. Therefore, these foreign nanoparticles are inevitably exposed to the immune system, which results in phagocytosis by the reticuloendothelial system and thus, loss of their biological significance. Immunocyte membranes play a key role in intercellular interactions, and can protect foreign nanomaterials as a natural barrier. Therefore, biomimetic nanotechnology based on cell membranes has developed rapidly in recent years. This paper summarizes the development of immunocyte membrane-coated nanoparticles in the immunotherapy of tumors. We will introduce several immunocyte membrane-coated nanocarriers and review the challenges to their large-scale preparation and application.

show abstract

“…Sun et al [74] developed PLGA NPs covered with macrophage membrane and loaded them with the anticancer drug Saikosaponin D to treat breast cancer and to overcome the drug toxicity. Because of the presence of T7 peptide on macrophages membrane, these NPs targeted breast cancer cells, showing an overexpression of the transferrin receptors.…”

Section: Toxicity and Biological Impact Of Biomimetic Npsmentioning

confidence: 99%

Biomimetic Nanocarriers for Cancer Target Therapy

et al. 2020

View full text Add to dashboard Cite

Nanotechnology offers innovative tools for the design of biomimetic nanocarriers for targeted cancer therapy. These nano-systems present several advantages such as cargo’s protection and modulation of its release, inclusion of stimuli-responsive elements, and enhanced tumoral accumulation. All together, these nano-systems suffer low therapeutic efficacy in vivo because organisms can recognize and remove foreign nanomaterials. To overcome this important issue, different modifications on nanoparticle surfaces were exploited in order to reach the desired therapeutic efficacy eliciting, also, the response of immune system against cancer cells. For this reason, more recently, a new strategy involving cell membrane-covered nanoparticles for biomedical application has been attracting increasing attention. Membranes from red blood cells, platelets, leukocytes, tumor, and stem cells, have been exploited as biomimetic coatings of nanoparticles for evading clearance or stimulated immune system by maintaining in the same way their targeting capability. In this review, the use of different cell sources as coating of biomimetic nanocarriers for cancer therapy is discussed.

show abstract

Saikosaponin D loaded macrophage membrane-biomimetic nanoparticles target angiogenic signaling for breast cancer therapy

Cited by 53 publications

References 44 publications

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Biomimetic Nanocarriers for Cancer Target Therapy

Contact Info

Product

Resources

About

Saikosaponin D loaded macrophage membrane-biomimetic nanoparticles target angiogenic signaling for breast cancer therapy

Cited by 53 publications

References 44 publications

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m6A signaling

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m6A signaling

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

Biomimetic Nanocarriers for Cancer Target Therapy

Contact Info

Product

Resources

About

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling

Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m⁶A signaling